Getting an x-ray is no big deal. It is very easily done. And then, the software will basically give you the coordinates of where the anticipated – the place to dropped your needle and the lead is. So this is about moving creating efficiency and moving things along faster, and easier and more and to be more comfortable for the patient and a quicker way to be able to get the external trial executed. So I think it’s flat-out as we stated that, right. I mean, the reason we’ve acquired this is, so, we can just make it easier for our customers to do the external file, which is required by insurance companies or private insurance companies or Medicare to be able to get paid. So, this is a necessary part of our business. And we thought this is a great opportunity for us to be able to facilitate it.
Particularly now as more ATP’s more of the advanced nursing practitioners are starting to do these procedures themselves as opposed to physicians. So, this is one more example of Axonics being innovative of looking at ways to be able to make this a much more efficient and effective, not necessarily effective, but more efficient procedure and therapy for patients and for our customers. So, we’re excited about it and I can tell you that, man, this is a big discussion at AUA, I mean, doc’s are over the moon about what we’ve done here and appreciate that we’re continuing to innovate. I mean, there’s been more changes and I know it’s unfortunate that this is seems to have escaped a lot of folks, but we’ve created more changes in the three and a half years that we’ve been in this market than the previous twenty something years.
So, I can tell you that the customers, the physicians themselves really appreciate the fact that Axonics is committed to continually looking at ways to make things faster and easier for them.
Michael Polark: Thanks, Ray.
Operator: Thank you. One moment for our next question. And our next question comes from the line of Shagun Singh from RBC Capital Markets. Your question, please.
Shagun Singh: Great. Thank you so much for taking the question and congratulations on a strong quarter. Just a couple of questions from me. You did note that SNM sales were driven by high utilization in existing accounts, as well as continued share gains. Can you elaborate or provide any quantification there? And then, as we look at the beats in the past couple of quarters, it seems like it’s more driven by Bulkamid and less by SNM. I’m just wondering if there is anything to read into that or not? Any commentary on competition or PDMS products? And then, I guess, on Medi-Cal, we were just hearing that they’re not reimbursing two procedures the trial of the implant. Is that true? And just any response there would be great. Thank you so much.
Raymond Cohen : Okay. So – I – you asked about five or six questions, this on – I got – we’re going to have to go one-by-one. Let’s take the last comment that you made. What was the last comment?
